StockData

Insight Molecular Diagnostics vs VolitionRx

IMDX and VNRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IMDX and VNRX compare

Insight Molecular Diagnostics is the larger company, worth 22 times as much as VolitionRx ($60.9M against $2.7M).

VolitionRx grew revenue faster over the last twelve months (86.3% versus −60.8% for Insight Molecular Diagnostics).

VolitionRx keeps more of each dollar of sales as profit, with a net margin of −1043% compared with −2956% at Insight Molecular Diagnostics.

Insight Molecular Diagnostics scores higher on the StockData Score (7 against 4 for VolitionRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIMDXVNRX
Size and price
Market cap$60.9M$2.7M
Share price$1.86$0.200
Change, 1 year−76.3%−97.2%
Change, 5 years−96.1%−99.7%
Beta (5Y)2.602.19
Employees5875
StockData Score
Total score7 (better)4
Valuation score01 (better)
Growth score12 (better)
Performance score11
Health score5 (better)0
Dividend score00
Valuation
P/S36.4×1.1× (better)
FCF yield−50.9% (better)−718%
Growth
Revenue growth (TTM)−60.8%86.3% (better)
Revenue growth, 5Y average27.2%164% (better)
Profitability
Gross margin48.3%–
Operating margin−3012%−790% (better)
Net margin−2956%−1043% (better)
FCF margin−1856%−797% (better)
Financial health
Current ratio2.00 (better)0.30
Altman Z-score−24.24 (better)−53.84
Piotroski F-score4 (better)2
Dividends and buybacks
Buyback yield−42.8% (better)−709%
Shareholder yield−42.8% (better)−709%
Ownership
Held by institutions56.4%14.1%
Held by insiders81.6%–
Insider net buying, 12 months$5.7M (better)$0
Short interest, % of float17.0%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.